PharmaSGP Holding SE: Annual General Meeting Approves Profit Distribution

German OTC pharmaceutical company PharmaSGP Holding SE held its Annual General Meeting in Munich on June 27, 2024. The meeting saw 89.74% of the share capital represented, and all agenda items were approved. Shareholders agreed to an increased dividend distribution of €1.36 per share.

In 2023, PharmaSGP's revenue exceeded €100 million for the first time, reaching €101.1 million, a 17.8% increase from the previous year. Adjusted EBITDA also rose by 20.8% to €34.1 million, with the EBITDA margin improving to 33.7%.

Shareholders will benefit from the Group’s strong financial performance with the full distribution of the 2023 profit. The appointment of Peter Gerckens as Chief Commercial Officer from July 1, 2024, aims to support the company's growth ambitions.

For 2024, the company forecasts revenues between €107.0 million and €112.0 million and an adjusted EBITDA of €35.0 million to €38.0 million, maintaining a margin of 32.7% to 33.9%.